Lawson Kroeker Investment Management Inc. NE Cuts Stake in Johnson & Johnson $JNJ

Lawson Kroeker Investment Management Inc. NE decreased its stake in Johnson & Johnson (NYSE:JNJ) by 6.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 47,995 shares of the company’s stock after selling 3,390 shares during the period. Johnson & Johnson makes up 1.6% of Lawson Kroeker Investment Management Inc. NE’s portfolio, making the stock its 19th biggest position. Lawson Kroeker Investment Management Inc. NE’s holdings in Johnson & Johnson were worth $8,899,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also modified their holdings of the stock. Kieckhefer Group LLC raised its holdings in shares of Johnson & Johnson by 13.2% during the 3rd quarter. Kieckhefer Group LLC now owns 2,150 shares of the company’s stock valued at $399,000 after buying an additional 250 shares during the period. Rooted Wealth Advisors Inc. grew its position in Johnson & Johnson by 29.2% in the third quarter. Rooted Wealth Advisors Inc. now owns 1,765 shares of the company’s stock valued at $333,000 after acquiring an additional 399 shares in the last quarter. waypoint wealth counsel grew its position in Johnson & Johnson by 12.7% in the third quarter. waypoint wealth counsel now owns 7,230 shares of the company’s stock valued at $1,341,000 after acquiring an additional 813 shares in the last quarter. Albion Financial Group UT lifted its position in shares of Johnson & Johnson by 5.5% during the third quarter. Albion Financial Group UT now owns 9,308 shares of the company’s stock worth $1,726,000 after purchasing an additional 484 shares in the last quarter. Finally, Tripletail Wealth Management LLC acquired a new position in shares of Johnson & Johnson during the third quarter worth $61,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Up 0.1%

NYSE:JNJ opened at $207.07 on Friday. The company has a market cap of $498.89 billion, a PE ratio of 19.99, a P/E/G ratio of 2.24 and a beta of 0.36. The business’s 50 day moving average is $200.83 and its two-hundred day moving average is $182.27. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $215.18.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The business had revenue of $24.02 billion for the quarter. On average, analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th were issued a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, November 25th. This represents a $5.20 annualized dividend and a dividend yield of 2.5%. Johnson & Johnson’s payout ratio is 50.19%.

Analysts Set New Price Targets

Several research firms recently issued reports on JNJ. JPMorgan Chase & Co. lifted their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 16th. Loop Capital set a $190.00 target price on Johnson & Johnson in a research report on Wednesday, October 22nd. BMO Capital Markets reissued an “outperform” rating on shares of Johnson & Johnson in a report on Thursday, December 11th. Johnson Rice set a $190.00 price objective on Johnson & Johnson and gave the company a “hold” rating in a research note on Wednesday, October 22nd. Finally, Scotiabank started coverage on Johnson & Johnson in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $230.00 target price on the stock. Four analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus target price of $211.25.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.